The Pharmaceuticals and Medical Devices Agency (PMDA) announced that the SHINSA companion diagnostic (CDx) has received approval for use in identifying patients who are eligible for certain treatments. The approval was updated on June 16, 2026. Further details are available on the PMDA website.
Actualizaciones regulatorias23 ago 2026•1 min de lectura
PMDA Approves SHINSA CDx for Identifying Eligible Patients
Japan’s PMDA has approved the SHINSA companion diagnostic (CDx) to help identify patients eligible for specific therapies, updated June 16, 2026.
Recopilado por el equipo de PharmaCountry · Fuente: PMDA Japan
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración